Long-Term Clinical Efficacy, Safety, and Polypharmacy Simplification of Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: An 18-Month Longitudinal Study
Background: Advanced Parkinson’s disease (aPD) is characterized by motor fluctuations, unpredictable oral absorption, and severe dyskinesias. Levodopa–entacapone–carbidopa intestinal gel (LECIG) is designed to provide dopaminergic stimulation and optimize levodopa bioavailability. We evaluated 18-month clinical outcome...